Dare Bioscience (DARE) Cash from Operations (2013 - 2025)
Dare Bioscience's (DARE) quarterly Cash from Operations came in at 1444264.0 in Q4 2025, down 72.78% YoY from 5305918.0 in Q4 2024, and up 426.66% on a QoQ basis from 442135.0 in Q3 2025.
Dare Bioscience (DARE) Cash from Operations (2013 - 2025) Analysis & Trends
Dare Bioscience (DARE) has 13 years of Cash from Operations data on file, last reported at 1444264.0 in Q4 2025.
- Quarterly Cash from Operations fell 72.78% year-over-year to 1444264.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 9885870.0 (down 280.61% YoY) and the FY2025 annual result came in at 9885870.0, down 280.61% from the prior year.
- Cash from Operations grew to 1444264.0 in Q4 2025, from 442135.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 12904685.0 in Q2 2024 to a low of 16117571.0 in Q1 2023.
- A 5-year average of 4506071.75 and a median of 6255216.5 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations soared 551.37% — and 2023, when it sank 192.72%.
- Tracing DARE's Cash from Operations over 5 years: stood at 9915899.0 in 2021, then surged by 40.53% to 5896672.0 in 2022, then tumbled by 38.7% to 8178905.0 in 2023, then soared by 164.87% to 5305918.0 in 2024, then tumbled by 72.78% to 1444264.0 in 2025.
- The last three Cash from Operations figures came in at 1444264.0 (Q4 2025), 442135.0 (Q3 2025), and 5387999.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Dare Bioscience | 12.36 Mn | -256,055.23 | -132,343.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.44 Mn |
| Dec 31, 2025 | 1.44 Mn |
| Sep 30, 2025 | -442,135.00 |
| Sep 30, 2025 | -442,135.00 |
| Jun 30, 2025 | -5.39 Mn |
| Jun 30, 2025 | -5.39 Mn |
| Mar 31, 2025 | -5.50 Mn |
| Mar 31, 2025 | -5.50 Mn |
| Dec 31, 2024 | 5.31 Mn |
| Dec 31, 2024 | 5.31 Mn |
| Sep 30, 2024 | -5.92 Mn |
| Sep 30, 2024 | -5.92 Mn |
| Jun 30, 2024 | 12.90 Mn |
| Jun 30, 2024 | 12.90 Mn |
| Mar 31, 2024 | -6.81 Mn |
| Mar 31, 2024 | -6.81 Mn |
| Dec 31, 2023 | -8.18 Mn |
| Dec 31, 2023 | -8.18 Mn |
| Sep 30, 2023 | -7.97 Mn |
| Sep 30, 2023 | -7.97 Mn |